TP53 mutations induced by BPDE in Xpa-WT and Xpa-Null human TP53 knock-in (Hupki) mouse embryo fibroblasts

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 773, Issue , 2015, Pages 48-62

  Kucab, Jill E ^a   van Steeg, Harry ^b   Luijten, Mirjam ^b   Schmeiser, Heinz H ^c   White, Paul A ^d   Phillips, David H ^a   Arlt, Volker M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HEALTH CANADA   (Canada)

Author keywords

Benzo a pyrene; DNA adducts; Environmental carcinogen; Mutation; Nucleotide excision repair; TP53

Indexed keywords

7,8 DIHYDROXYBENZO[A]PYRENE 9,10 OXIDE; PROTEIN P53; BENZO[A]PYRENE; BENZO[A]PYRENE 7,8 DIHYDRODIOL 9,10 OXIDE; CODON; DNA ADDUCT; MUTAGENIC AGENT; OXYGEN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XPA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CELL SURVIVAL; CODON; CONTROLLED STUDY; CPG ISLAND; CROSS BREEDING; DNA ADDUCT; EMBRYO; EXCISION REPAIR; EXON; FEMALE; FIBROBLAST; GENE SEQUENCE; GENOTYPE; KNOCKOUT MOUSE; MOUSE; MUTAGENESIS; NONHUMAN; SOMATIC MUTATION; TP53 GENE; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; CELL CULTURE; DNA REPAIR; DRUG EFFECTS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY;

MUS;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; ANIMALS; BENZO(A)PYRENE; CELL SURVIVAL; CELLS, CULTURED; CODON; DNA ADDUCTS; DNA REPAIR; FIBROBLASTS; GENES, P53; HUMANS; MICE; MUTAGENS; MUTATION; OXYGEN; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84922985390     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2015.01.013     Document Type: Article

References (75)

1. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
2. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
3. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
4. Hollstein M., Sidransky D., Vogelstein B.C.C. Harris, p53 mutations in human cancers. Science 1991, 253:49-53.
5. Hainaut P.M. Hollstein, p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
6. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspect. Biol. 2010, 2:a001008.
7. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
8. Schetter A.J., Harris C.C. Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7955-7956.
9. Luo J.L., Yang Q., Tong W.M., Hergenhahn M., Wang Z.Q., Hollstein M. Knock-in mice with a chimeric human/murine p53 gene develop normally and show wild-type p53 responses to DNA damaging agents: a new biomedical research tool. Oncogene 2001, 20:320-328.
10. Kucab J.E., Phillips D.H., Arlt V.M. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J. 2010, 277:2567-2583.
11. Besaratinia A., Pfeifer G.P. Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 2010, 24:2612-2619.
12. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2963-2968.
13. Liu Z., Muehlbauer K.R., Schmeiser H.H., Hergenhahn M., Belharazem D.M.C. Hollstein, p53 mutations in benzo(a)pyrene-exposed human p53 knock-in murine fibroblasts correlate with p53 mutations in human lung tumors. Cancer Res. 2005, 65:2583-2587.
14. Reinbold M., Luo J.L., Nedelko T., Jerchow B., Murphy M.E., Whibley C., Wei Q., Hollstein M. Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72. Oncogene 2008, 27:2788-2794.
15. Nedelko T., Arlt V.M., Phillips D.H., Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer 2009, 124:987-990.
16. Friedberg E.C. How nucleotide excision repair protects against cancer. Nat. Rev. Cancer 2001, 1:22-33.
17. Scharer O.D. Nucleotide excision repair in eukaryotes. Cold Spring Harbor Perspect. Biol. 2013, 5:a012609.
18. de Vries A., van Oostrom C.T., Hofhuis F.M., Dortant P.M., Berg R.J., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J., van Steeg H., et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 1995, 377:169-173.
19. Berg R.J., de Vries A., van Steeg H., de Gruijl F.R. Relative susceptibilities of XPA knockout mice and their heterozygous and wild-type littermates to UVB-induced skin cancer. Cancer Res. 1997, 57:581-584.
20. van Steeg H., de Vries A., van Oostrom C., van Benthem J., Beems R.B., van Kreijl C.F. DNA repair-deficient Xpa and Xpa/p53+/- knock-out mice: nature of the models. Toxicol. Pathol. 2001, 29(Suppl.):109-116.
21. Klein J.C., Beems R.B., Zwart P.E., Hamzink M., Zomer G., van Steeg H., van Kreijl C.F. Intestinal toxicity and carcinogenic potential of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4 5-b]pyridine (PhIP) in DNA repair deficient XPA-/-mice. Carcinogenesis 2001, 22:619-626.
22. de Vries A., Dolle M.E., Broekhof J.L., Muller J.J., Kroese E.D., van Kreijl C.F., Capel P.J., Vijg J., van Steeg H. Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. Carcinogenesis 1997, 18:2327-2332.
23. Hoogervorst E.M., de Vries A., Beems R.B., van Oostrom C.T., Wester P.W., Vos J.G., Bruins W., Roodbergen M., Cassee F.R., Vijg J., van Schooten F.J., van Steeg H. Combined oral benzo[a]pyrene and inhalatory ozone exposure have no effect on lung tumor development in DNA repair-deficient Xpa mice. Carcinogenesis 2003, 24:613-619.
24. Rebel H., Mosnier L.O., Berg R.J., Westerman-de Vries A., van Steeg H., van Kranen H.J., de Gruijl F.R. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency, and p53 heterozygosity. Cancer Res. 2001, 61:977-983.
25. Ames B.N., McCann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat. Res. 1975, 31:347-364.
26. Thompson L.H., Salazar E.P., Brookman K.W., Hoy C.A. Hypersensitivity to cell killing and mutation induction by chemical carcinogens in an excision repair-deficient mutant of CHO cells. Mutat. Res. 1983, 112:329-344.
27. Tanaka K., Kamiuchi S., Ren Y., Yonemasu R., Ichikawa M., Murai H., Yoshino M., Takeuchi S., Saijo M., Nakatsu Y., Miyauchi-Hashimoto H., Horio T. UV-induced skin carcinogenesis in xeroderma pigmentosum group A (XPA) gene-knockout mice with nucleotide excision repair-deficiency. Mutat. Res. 2001, 477:31-40.
28. Arlt V.M., Stiborova M., Henderson C.J., Thiemann M., Frei E., Aimova D., Singh R., Gamboa da Costa G., Schmitz O.J., Farmer P.B., Wolf C.R., Phillips D.H. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis 2008, 29:656-665.
29. Stiborova M., Moserova M., Cerna V., Indra R., Dracinsky M., Sulc M., Henderson C.J., Wolf C.R., Schmeiser H.H., Phillips D.H., Frei E., Arlt V.M. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions. Toxicology 2014, 318:1-12.
30. H. Naegeli, N.E. Geacintov, Mechanisms of repair of polycyclic aromatic hydrocarbon-induced DNA damage, in: The Carcinogenic Effects of Polycyclic Aromatic Hydrocarbons, pp. 211-258.
31. Harvey R.G., Fu P.P. Synthesis and reactions of diol epoxides and related metabolites of carcinogenic hydrocarbons. Polycyclic Hydrocarbons and Cancer 1978, 133-165. Academic Press, New York. H.V. Gelboin, P.O.P. Ts'o (Eds.).
32. Arlt V.M., Poirier M.C., Sykes S.E., John K., Moserova M., Stiborova M., Roland Wolf C., Henderson C.J., Phillips D.H. Exposure to benzo[a]pyrene of Hepatic Cytochrome P450 Reductase Null (HRN) and P450 Reductase Conditional Null (RCN) mice: Detection of benzo[a]pyrene diol epoxide-DNA adducts by immunohistochemistry and (32)P-postlabelling. Toxicol. Lett. 2012, 213:160-166.
33. Phillips D.H., Arlt V.M. (3)(2)P-postlabeling analysis of DNA adducts. Methods Mol. Biol. (Clifton, N.J.) 2014, 1105:127-138.
34. Hockley S.L., Arlt V.M., Jahnke G., Hartwig A., Giddings I., Phillips D.H. Identification through microarray gene expression analysis of cellular responses to benzo(a)pyrene and its diol-epoxide that are dependent or independent of p53. Carcinogenesis 2008, 29:202-210.
35. Csete M. Oxygen in the cultivation of stem cells. Ann. N. Y. Acad. Sci. 2005, 1049:1-8.
36. Hornsby P.J. Mouse and human cells versus oxygen. Sci. Aging Knowledge Environ. 2003 2003, PE21.
37. Parrinello S., Samper E., Krtolica A., Goldstein J., Melov S., Campisi J. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 2003, 5:741-747.
38. Dooley T.P., Gadwood R.C., Kilgore K., Thomasco L.M. Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. Skin Pharmacol. 1994, 7:188-200.
39. Liu Z., Belharazem D., Muehlbauer K.R., Nedelko T., Knyazev Y., Hollstein M. Mutagenesis of human p53 tumor suppressor gene sequences in embryonic fibroblasts of genetically-engineered mice. Genet. Eng. (N. Y.) 2007, 28:45-54.
40. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 1987, 194:391-396.
41. Cariello N.F., Piegorsch W.W., Adams W.T., Skopek T.R. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis 1994, 15:2281-2285.
42. Colton S.L., Xu X.S., Wang Y.A., Wang G. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment. J. Biol. Chem. 2006, 281:27117-27125.
43. Ogi T., Shinkai Y., Tanaka K., Ohmori H. Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15548-15553.
44. Dreij K., Seidel A., Jernstrom B. Differential removal of DNA adducts derived from anti-diol epoxides of dibenzo[a,l]pyrene and benzo[a]pyrene in human cells. Chem. Res. Toxicol. 2005, 18:655-664.
45. Lagerqvist A., Hakansson D., Prochazka G., Lundin C., Dreij K., Segerback D., Jernstrom B., Tornqvist M., Seidel A., Erixon K., Jenssen D. Both replication bypass fidelity and repair efficiency influence the yield of mutations per target dose in intact mammalian cells induced by benzo[a]pyrene-diol-epoxide and dibenzo[a l]pyrene-diol-epoxide. DNA Rep. (Amst.) 2008, 7:1202-1212.
46. Lloyd D.R., Hanawalt P.C. p53-dependent global genomic repair of benzo[a]pyrene-7 8-diol-9,10-epoxide adducts in human cells. Cancer Res. 2000, 60:517-521.
47. Denissenko M.F., Pao A., Pfeifer G.P., Tang M. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 1998, 16:1241-1247.
48. Ford J.M., Lommel L., Hanawalt P.C. Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. Mol. Carcinog. 1994, 10:105-109.
49. Pfeifer G.P., Hainaut P. On the origin of G --> T transversions in lung cancer. Mutat. Res. 2003, 526:39-43.
50. Chen R.H., Maher V.M., McCormick J.J. Lack of a cell cycle-dependent strand bias for mutations induced in the HPRT gene by (+/-)-7 beta 8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in excision repair-deficient human cells. Cancer Res. 1991, 51:2587-2592.
51. Schiltz M., Cui X.X., Lu Y.P., Yagi H., Jerina D.M., Zdzienicka M.Z., Chang R.L., Conney A.H., Wei S.J. Characterization of the mutational profile of (+)-7R 8S-dihydroxy-9S, 10R-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene at the hypoxanthine (guanine) phosphoribosyltransferase gene in repair-deficient Chinese hamster V-H1 cells. Carcinogenesis 1999, 20:2279-2286.
52. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8424-8429.
53. Whibley C., Odell A.F., Nedelko T., Balaburski G., Murphy M., Liu Z., Stevens L., Walker J.H., Routledge M., Hollstein M. Wild-type and Hupki (human p53 knock-in) murine embryonic fibroblasts: p53/ARF pathway disruption in spontaneous escape from senescence. J. Biol. Chem. 2010, 285:11326-11335.
54. Ljungman M., Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene 1996, 13:823-831.
55. de Waard H., Sonneveld E., de Wit J., Esveldt-van Lange R., Hoeijmakers J.H., Vrieling H., van der Horst G.T. Cell-type-specific consequences of nucleotide excision repair deficiencies: embryonic stem cells versus fibroblasts. DNA Rep. (Amst.) 2008, 7:1659-1669.
56. Ljungman M., Lane D.P., Transcription guarding the genome by sensing DNA damage. Nat. Rev. Cancer 2004, 4:727-737.
57. Imaida K., Ogawa K., Takahashi S., Ito T., Yamaguchi T., Totsuka Y., Wakabayashi K., Tanaka K., Ito N., Shirai T. Delay of DNA-adduct repair and severe toxicity in xeroderma pigmentosum group A gene (XPA) deficient mice treated with 2-amino-1-methyl-6-phenyl-imidazo [4 5-b] pyridine (PhIP). Cancer Lett. 2000, 150:63-69.
58. Berg R.J., Ruven H.J., Sands A.T., de Gruijl F.R., Mullenders L.H. Defective global genome repair in XPC mice is associated with skin cancer susceptibility but not with sensitivity to UVB induced erythema and edema. J. Invest. Dermatol. 1998, 110:405-409.
59. van Kesteren P.C., Zwart P.E., Schaap M.M., Pronk T.E., van Herwijnen M.H., Kleinjans J.C., Bokkers B.G., Godschalk R.W., Zeilmaker M.J., van Steeg H., Luijten M. Benzo[a]pyrene-induced transcriptomic responses in primary hepatocytes and in vivo liver: toxicokinetics is essential for in vivo-in vitro comparisons. Arch. Toxicol. Epub. 2012, 2012/2010/2012.
60. Venkatachalam S., Denissenko M., Wani A.A. DNA repair in human cells: quantitative assessment of bulky anti-BPDE-DNA adducts by non-competitive immunoassays. Carcinogenesis 1995, 16:2029-2036.
61. Ruggeri B., DiRado M., Zhang S.Y., Bauer B., Goodrow T., Klein-Szanto A.J. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1013-1017.
62. Eisenstadt E., Warren A.J., Porter J., Atkins D., Miller J.H. Carcinogenic epoxides of benzo[a]pyrene and cyclopenta[cd]pyrene induce base substitutions via specific transversions. Proc. Natl. Acad. Sci. U. S. A. 1982, 79:1945-1949.
63. Denissenko M.F., Chen J.X., Tang M.S., Pfeifer G.P. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3893-3898.
64. Pfeifer G.P. p53 mutational spectra and the role of methylated CpG sequences. Mutat. Res. 2000, 450:155-166.
65. Geacintov N.E., Shahbaz M., Ibanez V., Moussaoui K., Harvey R.G. Base-sequence dependence of noncovalent complex formation and reactivity of benzo[a]pyrenediol epoxide with polynucleotides. Biochemistry 1988, 27:8380-8387.
66. Sowers L.C., Shaw B.R., Sedwick W.D. Base stacking and molecular polarizability: effect of a methyl group in the 5-position of pyrimidines. Biochem. Biophys. Res. Commun. 1987, 148:790-794.
67. Johnson W.S., He Q.Y., Tomasz M. Selective recognition of the m5CpG dinucleotide sequence in DNA by mitomycin C for alkylation and cross-linking. Bioorg. Med. Chem. 1995, 3:851-860.
68. Kim S.I., Hollstein M., Pfeifer G.P., Besaratinia A. Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome. Mol. Carcinog. 2010, 49:999-1006.
69. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996, 274:430-432.
70. Rodriguez F.A., Cai Y., Lin C., Tang Y., Kolbanovskiy A., Amin S., Patel D.J., Broyde S., Geacintov N.E. Exocyclic amino groups of flanking guanines govern sequence-dependent adduct conformations and local structural distortions for minor groove-aligned benzo[a]pyrenyl-guanine lesions in a GG mutation hotspot context. Nucleic Acids Res. 2007, 35:1555-1568.
71. Rodriguez H., Loechler E.L. Mutational specificity of the (+)-anti-diol epoxide of benzo[a]pyrene in a supF gene of an Escherichia coli plasmid: DNA sequence context influences hotspots, mutagenic specificity and the extent of SOS enhancement of mutagenesis. Carcinogenesis 1993, 14:373-383.
72. van Schooten F.J., Schults M., Sanen K., Godschalk R., Theys J., Chiu R. Hypoxia affects the metabolic activation and detoxification of the environmental mutagen benzo(a)pyrene. Cancer Res. 2012, pp. Abstract 4118.
73. Olivier M., Weninger A., Ardin M., Huskova H., Castells X., Vallee M.P., McKay J., Nedelko T., Muehlbauer K.R., Marusawa H., Alexander J., Hazelwood L., Byrnes G., Hollstein M., Zavadil J. Modelling mutational landscapes of human cancers in vitro. Scient. Rep. 2014, 4:4482.
74. DeMarini D.M., Landi S., Tian D., Hanley N.M., Li X., Hu F., Roop B.C., Mass M.J., Keohavong P., Gao W., Olivier M., Hainaut P., Mumford J.L. Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissions. Cancer Res. 2001, 61:6679-6681.
75. Sarkar F.H., Li Y., Vallyathan V. Molecular analysis of p53 and K-ras in lung carcinomas of coal miners. Int. J. Mol. Med. 2001, 8:453-459.